Cyclo (CKLIIF) (TFA)

Cyclo CKLIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains KD of 2.6 and 2.2 μM, respectively[1].

Product Specifications

UNSPSC

12352209

Target

HIF/HIF Prolyl-Hydroxylase

Type

Peptides

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cyclo-ckliif-tfa.html

Purity

98.07

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@@H](C)CC)C(N[C@H]1CC2=CC=CC=C2)=O)=O)=O)=O)[C@H](CS)NC1=O.O=C(O)C(F)(F)F

Molecular Formula

C38H60F3N7O8S

Molecular Weight

831.99

References & Citations

[1]Ball AT, et al., Identification and Development of Cyclic Peptide Inhibitors of Hypoxia Inducible Factors 1 and 2 That Disrupt Hypoxia-Response Signaling in Cancer Cells. J Am Chem Soc. 2024 Mar 19.